Related Experiment Video
Updated: May 16, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Rehospitalization for heart failure: problems and perspectives
Mihai Gheorghiade1, Muthiah Vaduganathan2, Gregg C Fonarow3
1Center for Cardiovascular Innovation at Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract:
With a prevalence of 5.8 million in the United States alone, heart failure (HF) is associated with high morbidity, mortality, and healthcare expenditures. Close to 1 million hospitalizations for heart failure (HHF) occur annually, accounting for over 6.5 million hospital days and a substantial portion of the estimated $37.2 billion that is spent each year on HF in the United States. Although some progress has been made in reducing mortality in patients hospitalized with HF, rates of rehospitalization continue to rise, and approach 30% within 60 to 90 days of discharge. Approximately half of HHF patients have preserved or relatively preserved ejection fraction (EF). Their post-discharge event rate is similar to those with reduced EF. HF readmission is increasingly being used as a quality metric, a basis for hospital reimbursement, and an outcome measure in HF clinical trials. In order to effectively prevent HF readmissions and improve overall outcomes, it is important to have a complete and longitudinal characterization of HHF patients. This paper highlights management strategies that when properly implemented may help reduce HF rehospitalizations and include adopting a mechanistic approach to cardiac abnormalities, treating noncardiac comorbidities, increasing utilization of evidence-based therapies, and improving care transitions, monitoring, and disease management.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Heart Failure I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation
Rheumatic Heart Disease III: Medical Management

